News Column

Rare Performance Bolsters Nuvilex's Approval Prospects

Jun 10 2013 12:00AM

Marketwire

Tracker

BALTIMORE, MD -- (Marketwired) -- 06/10/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that the rare combination of large early stage investments in its pancreatic cancer R&D program and its Phase II clinical trial performance strongly bolsters Nuvilex's (OTCQB: NVLX) prospects for approval of its treatment for advanced inoperable pancreatic cancer. The Company is an international firm engaged in using its live-cell encapsulation technology as part of treatments for pancreatic and other cancers along with the development of therapies based on components of medical marijuana for the treatment of oncology patients.

To date, nearly $30M has been invested in the Company's live-cell encapsulation-based therapies to treat pancreatic cancer and other diseases. This includes two successful Phase II clinical trials in pancreatic cancer, preclinical trials for other cancer indications, and additional product development. Research and development expenses do not end at the conclusion of trials, however; $2M has been invested in the past 2 years alone to help further the Company's development goals.

This cumulative $30M investment has resulted in something rare for biotech companies and enhances the likelihood of Nuvilex's continued success with the ultimate goal of FDA approval and commercialization of its products. A recent study has demonstrated that in the past few years, 82% of companies engaged in Phase II clinical trials have failed due to insufficient efficacy or serious toxicity. This means that Nuvilex is in the 18% minority of firms that have produced favorable results.

Not only is it rare for a firm like Nuvilex to have such success in Phase II trials, but given the excellent trial results, surely a new trial that compares Nuvilex's treatment "head-to-head" with the gold standard pancreatic cancer treatment Gemzar, has significant potential for success. Given that Gemzar generates annual sales north of $1 billion annually, the Company's previous and future R&D investments could have a huge return on investment for Nuvilex and its shareholders.

A copy of this article as well as other articles and Nuvilex reports can be accessed by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.



Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com





Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters